Navidea Biopharmaceuticals (NAVB) Earnings Date, Estimates & Call Transcripts $0.0010 0.00 (0.00%) (As of 03:46 PM ET) Add Compare Share Share Earnings Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsTrends Get Navidea Biopharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Navidea Biopharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataNAVB Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NAVB Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad TradingTips3 Dirt-Cheap Stocks You Can’t Afford to Ignore Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.Get your FREE look at these THREE companies right here. Navidea Biopharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks11/14/2023Q3 2023--$0.02 -$0.02-$0.02--8/11/2023Q2 2023--$0.03 -$0.03-$0.18--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05-- Get the Latest News and Ratings for NAVB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--5/11/2023Q1 2023--$0.05 -$0.05-$0.05--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--3/21/2023Q4 2022--$0.11 -$0.11-$0.11--Central Bank Abandons USD (Ad)Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide.11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M11/14/2022Q3 2022--$0.25 -$0.25-$0.25-$0.01M ` More Earnings Resources from MarketBeat Related Companies TCON Earnings Date SMFL Earnings Date VAXX Earnings Date EVLO Earnings Date CMRA Earnings Date EFTR Earnings Date ALVO Earnings Date AMPE Earnings Date CLVR Earnings Date MYNZ Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to Run 3 Dirt-Cheap Stocks You Can’t Afford to Ignore (Ad)Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.Get your FREE look at these THREE companies right here. This page (NYSE:NAVB) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
